FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917504089> ?p ?o ?g. }

• W1917504089 endingPage "214" @default.
• W1917504089 startingPage "207" @default.
• W1917504089 abstract "To investigate the efficacy, safety, and tolerability of weekly docetaxel treatment in advanced non-small cell lung cancer (NSCLC) patients in Korea.This prospective observational study included Korean advanced NSCLC patients with Eastern Cooperative Oncology Group performance status <2 who received weekly monotherapy of docetaxel at a dose determined by the physician. Efficacy measurements included tumor response rate, overall survival (OS), progression-free survival, and one-year survival rate. Safety was analyzed through recorded incidences of adverse events (AEs), serious adverse events (SAEs), deaths, and other related safety parameters, along with their toxicity grades.Of 274 patients analyzed, one patient achieved a complete response and 42 partial responses; thus, the overall response rate was 15.7%. The OS rate at baseline and at one-year follow-up was 38.3% and 33.8%, respectively. AEs were reported in 229 (83.6%) patients. The most frequently reported hematologic AE of grade ≥3 was a decrease in neutrophils, with 6.6% of the patients developing neutropenia. In non-hematologic AEs of grade ≥3, the most common were infection with unknown absolute neutrophil count and death not associated with Common Terminology Criteria for Adverse Events (CTCAE) (4.7% each). The most common SAE reported was death, not associated with CTCAE (7.3%).In Korean patients, the weekly regimen of docetaxel monotherapy was safe and efficacious against advanced NSCLC." @default.
• W1917504089 created "2016-06-24" @default.
• W1917504089 creator A5005358526 @default.
• W1917504089 creator A5010555462 @default.
• W1917504089 creator A5011582408 @default.
• W1917504089 creator A5019303498 @default.
• W1917504089 creator A5020014692 @default.
• W1917504089 creator A5020992348 @default.
• W1917504089 creator A5021861062 @default.
• W1917504089 creator A5035986984 @default.
• W1917504089 creator A5036720036 @default.
• W1917504089 creator A5045192289 @default.
• W1917504089 creator A5053833862 @default.
• W1917504089 creator A5054752452 @default.
• W1917504089 creator A5057146015 @default.
• W1917504089 creator A5069869461 @default.
• W1917504089 creator A5086784581 @default.
• W1917504089 date "2015-11-01" @default.
• W1917504089 modified "2023-10-01" @default.
• W1917504089 title "Safety and efficacy of single‐agent docetaxel ( <scp>T</scp> axotere) administered weekly in non‐small cell lung carcinoma patients in <scp>K</scp> orea: An observational study" @default.
• W1917504089 cites W1839238860 @default.
• W1917504089 cites W1935885922 @default.
• W1917504089 cites W1973043804 @default.
• W1917504089 cites W1980085611 @default.
• W1917504089 cites W1985385147 @default.
• W1917504089 cites W2037139573 @default.
• W1917504089 cites W2037551340 @default.
• W1917504089 cites W2045168474 @default.
• W1917504089 cites W2053432470 @default.
• W1917504089 cites W2054841768 @default.
• W1917504089 cites W2067790939 @default.
• W1917504089 cites W2079419271 @default.
• W1917504089 cites W2088464819 @default.
• W1917504089 cites W2107263892 @default.
• W1917504089 cites W2112221008 @default.
• W1917504089 cites W2115751177 @default.
• W1917504089 cites W2118281867 @default.
• W1917504089 cites W2119366998 @default.
• W1917504089 cites W2119659897 @default.
• W1917504089 cites W2130652363 @default.
• W1917504089 cites W2133297657 @default.
• W1917504089 cites W2136023414 @default.
• W1917504089 cites W2142809967 @default.
• W1917504089 cites W2147075384 @default.
• W1917504089 cites W2148342468 @default.
• W1917504089 cites W2151522757 @default.
• W1917504089 cites W4234236664 @default.
• W1917504089 doi "https://doi.org/10.1111/1759-7714.12315" @default.
• W1917504089 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4773308" @default.
• W1917504089 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27042223" @default.
• W1917504089 hasPublicationYear "2015" @default.
• W1917504089 type Work @default.
• W1917504089 sameAs 1917504089 @default.
• W1917504089 citedByCount "2" @default.
• W1917504089 countsByYear W19175040892016 @default.
• W1917504089 countsByYear W19175040892022 @default.
• W1917504089 crossrefType "journal-article" @default.
• W1917504089 hasAuthorship W1917504089A5005358526 @default.
• W1917504089 hasAuthorship W1917504089A5010555462 @default.
• W1917504089 hasAuthorship W1917504089A5011582408 @default.
• W1917504089 hasAuthorship W1917504089A5019303498 @default.
• W1917504089 hasAuthorship W1917504089A5020014692 @default.
• W1917504089 hasAuthorship W1917504089A5020992348 @default.
• W1917504089 hasAuthorship W1917504089A5021861062 @default.
• W1917504089 hasAuthorship W1917504089A5035986984 @default.
• W1917504089 hasAuthorship W1917504089A5036720036 @default.
• W1917504089 hasAuthorship W1917504089A5045192289 @default.
• W1917504089 hasAuthorship W1917504089A5053833862 @default.
• W1917504089 hasAuthorship W1917504089A5054752452 @default.
• W1917504089 hasAuthorship W1917504089A5057146015 @default.
• W1917504089 hasAuthorship W1917504089A5069869461 @default.
• W1917504089 hasAuthorship W1917504089A5086784581 @default.
• W1917504089 hasBestOaLocation W19175040891 @default.
• W1917504089 hasConcept C121608353 @default.
• W1917504089 hasConcept C126322002 @default.
• W1917504089 hasConcept C143998085 @default.
• W1917504089 hasConcept C197934379 @default.
• W1917504089 hasConcept C2776256026 @default.
• W1917504089 hasConcept C2777063308 @default.
• W1917504089 hasConcept C2777793932 @default.
• W1917504089 hasConcept C2778375690 @default.
• W1917504089 hasConcept C2781190966 @default.
• W1917504089 hasConcept C2781413609 @default.
• W1917504089 hasConcept C29730261 @default.
• W1917504089 hasConcept C71924100 @default.
• W1917504089 hasConceptScore W1917504089C121608353 @default.
• W1917504089 hasConceptScore W1917504089C126322002 @default.
• W1917504089 hasConceptScore W1917504089C143998085 @default.
• W1917504089 hasConceptScore W1917504089C197934379 @default.
• W1917504089 hasConceptScore W1917504089C2776256026 @default.
• W1917504089 hasConceptScore W1917504089C2777063308 @default.
• W1917504089 hasConceptScore W1917504089C2777793932 @default.
• W1917504089 hasConceptScore W1917504089C2778375690 @default.
• W1917504089 hasConceptScore W1917504089C2781190966 @default.
• W1917504089 hasConceptScore W1917504089C2781413609 @default.
• W1917504089 hasConceptScore W1917504089C29730261 @default.
• W1917504089 hasConceptScore W1917504089C71924100 @default.
• W1917504089 hasIssue "2" @default.

• next